{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"132-256-994-317-894","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"132-256-994-317-894","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8635,"type":"PATENT","title":"MIT Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":30193,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8198,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Select Applicants and Owners= \"MIT\", \" Massachusetts Institute of Technology \", \"Massachus* Insti* Tech*\", \"Media Lab Massachus* Insti* Tech*\", \"Massachus* Tech* Inst*\".
Select more for logical variants
Add to collect
Note: over 20k
Select Applicants and Owners= \"MIT\", \" Massachusetts Institute of Technology \", \"Massachus* Insti* Tech*\", \"Media Lab Massachus* Insti* Tech*\", \"Massachus* Tech* Inst*\".
Select more for logical variants
Add to collect
Note: over 20k
administering to a subject in need of such treatment an effective amount of insulin-like growth factor 1 (IGF1) and/or (1-3)IGF-1, to treat the subject."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein IGF1 is administered."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the IGF1 is recombinant IGF1."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the IGF1 is human IGF1."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the dose of IGF1 administered is about 0.1-10 mg/kg/day."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 5, wherein the dose of IGF1 administered is about 0.1-2 mg/kg/day."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein (1-3)IGF-1 is administered."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 7, wherein the dose of (1-3)IGF-1 administered is about 0.1-100 mg/kg/day."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 8, wherein the dose of (1-3)IGF-1 administered is about 6-20 mg/kg/day."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the subject is a human."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the IGF1 and/or (1-3)IGF-1 is administered orally, intravenously, intramuscularly, intranasally, intraperitoneally, subcutaneously, or intrathecally."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the IGF1 and/or (1-3)IGF-1 is administered after diagnosis of Rett syndrome."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the IGF1 and/or (1-3)IGF-1 is administered to the subject based on clinical diagnosis of Rett syndrome prior to confirmation of MeCP2 deficiency."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the subject is free of symptoms otherwise calling for treatment with the IGF1 and/or (1-3)IGF-1."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, further comprising first testing the subject for a mutation in a gene coding for methyl CpG-binding protein 2 (MeCP2)."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, further comprising administering to the subject tPA, BDNF, or a benzodiazepine and wherein the tPA, BDNF or benzodiazepine and the IGF1 and/or (1-3)IGF-1 are administered in a combined amount effective to treat the subject."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the amount of IGF1 and/or (1-3)IGF-1 is effective to restore synaptic function and/or maturation, consolidate synapses and/or regulate neuronal plasticity."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the IGF1 and/or (1-3)IGF-1 is administered as a pharmaceutical composition."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, pharmaceutical composition comprises IGF1 and/or (1-3)IGF-1 combined with a stabilizing agent or carrier."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 19, wherein the stabilizing agent or carrier is a polyethylene glycol."],"number":20,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}